• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by KALA BIO Inc.

    1/6/25 8:06:27 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KALA alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001415537
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    KALA BIO, INC.
    SEC File Number
    001-38150
    Address of Issuer
    1167 MASSACHUSETTS AVENUE
    ARLINGTON
    MASSACHUSETTS
    02476
    Phone
    781-996-5252
    Name of Person for Whose Account the Securities are To Be Sold
    Mark T Iwicki
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer
    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    ETRADE FINANCIAL CORPORATION
    3 EDISON DRIVE
    ALPHARETTA � GA � 30005
    577944079.49609118201/06/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock01/06/2025Restricted Stock Unit VestingIssuerCheckbox not checked1866501/06/2025Equity Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Represents the sale of shares of common stock pursuant to a "sell-to-cover" transaction in order to satisfy tax withholding obligations in connection with the vesting of RSUs previously granted to the Reporting Person. This sale was effected pursuant to an automatic sell-to-cover instruction effected pursuant to Rule 10b5-1 adopted by the Reporting Person on November 9, 2020 and does not represent a discretionary sale by the Reporting Person.
    Date of Notice
    01/06/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Mary Reumuth, Attorney-in-Fact

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $KALA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KALA

    DatePrice TargetRatingAnalyst
    3/30/2022Neutral → Underweight
    JP Morgan
    8/6/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    8/6/2021Overweight → Neutral
    JP Morgan
    More analyst ratings

    $KALA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      -- Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) -- -- Continuing enrollment into 2Q25; currently targeting topline data in 3Q25 -- -- Raised $10.75 million in private placement financing with participation from SR One, Cormorant Asset Management, Woodline Partners and another life sciences-focused investor -- -- Cash resources of $51.2 million as of December 31, 2024, expected to fund operations into 1Q 2026 -- ARLINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies

      3/31/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO to Present at TD Cowen 45th Annual Health Care Conference

      ARLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that members of management will present at the TD Cowen 45th Annual Health Care Conference being held in Boston, MA on Wednesday, March 5, 2025 at 11:50 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 5, 2025. To access the webcast and subsequent archived recording of the presentation, please visit the "Presentations" section of the KALA website at www.kalarx.com. About KALA BIO, Inc. K

      2/26/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Leadership Updates

    Live Leadership Updates

    See more
    • KALA BIO Announces Chief Executive Officer Transition

      ARLINGTON, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the resignation of Chief Executive Officer (CEO) Mark Iwicki, and the appointment of Todd Bazemore, KALA's President and Chief Operating Officer, as interim CEO, effective immediately. Mr. Iwicki will continue to serve as Chair of the Board of Directors of KALA following the transition. Mr. Bazemore has served as KALA's President since December 2021 and as KALA's Chief Operating Officer since November 2017. Mr. Iwicki stated,

      2/12/25 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

      -- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 ---- Received FDA Fast Track designation for KPI-012 for the treatment of PCED ---- Strengthened clinical R&D team with appointment of Dr. Francis Mah as Chief Medical Advisor – -- Awarded $15 million grant from CIRM to support the KPI-012 PCED program -- ARLINGTON, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and sever

      5/9/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor

      ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced the appointment of Francis Mah, M.D., as Chief Medical Advisor. In this newly established role, Dr. Mah will provide support for Kala's clinical development and medical activities and will play a key role in interactions with eye care professionals. Dr. Mah will serve in this role on a part time basis while continuing his ongoing position as Director of Cornea and External Disease and the Co-Director, Refractive Su

      3/29/23 8:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      12/31/24 4:00:18 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by KALA BIO Inc.

      SC 13G - KALA BIO, Inc. (0001479419) (Subject)

      11/14/24 4:49:42 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      7/8/24 8:54:55 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by KALA BIO Inc.

      SC 13D - KALA BIO, Inc. (0001479419) (Subject)

      6/28/24 4:11:51 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Financials

    Live finance-specific insights

    See more

    $KALA
    SEC Filings

    See more

    $KALA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

      ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) ("Kala" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on August 29, 2022. The shares of Series D Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on August 30, 2022. The

      8/18/22 4:01:00 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      -- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and INVELTYS® to Alcon Inc. and Significantly Reduced Operating Expenses, Extending Cash Runway into 2Q 2024 -- -- Conference Call and Webcast at 8:00 a.m. ET -- ARLINGTON, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the second quarter ended June 30, 2022 and prov

      8/11/22 7:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

      ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. The dial-in number to access the conference call is 800-715-9871 using the conference ID 9372651. To access a live webcast and subsequent archived recording of the call, please visit the "Presentations" se

      8/8/22 9:00:00 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • KALA BIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - KALA BIO, Inc. (0001479419) (Filer)

      4/11/25 4:09:11 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by KALA BIO Inc.

      424B5 - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:45:34 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by KALA BIO Inc.

      10-K - KALA BIO, Inc. (0001479419) (Filer)

      3/31/25 8:03:08 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Officer Bazemore Todd

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      3/10/25 8:00:08 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Officer Brazzell Romulus K

      4/A - KALA BIO, Inc. (0001479419) (Issuer)

      1/10/25 8:00:36 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Bazemore Todd was granted 10,100 shares and sold $15,207 worth of shares (1,993 units at $7.63), increasing direct ownership by 10% to 91,147 units (SEC Form 4)

      4 - KALA BIO, Inc. (0001479419) (Issuer)

      1/7/25 8:14:03 PM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KALA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Neutral to Underweight

      3/30/22 7:39:31 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Kala Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Kala Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously

      8/6/21 6:36:47 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kala Pharmaceuticals downgraded by JP Morgan

      JP Morgan downgraded Kala Pharmaceuticals from Overweight to Neutral

      8/6/21 5:55:07 AM ET
      $KALA
      Biotechnology: Pharmaceutical Preparations
      Health Care